12/19/2023 0 Comments Amber lyn csulb![]() ![]() Dr Barouch reported receiving grants from the NIH, DAPRA, MassCPR, the Bill and Melinda Gates Foundation, South Africa MRC, the Henry M. Dr Barnabas reported receiving grants from the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation and receiving support for conference abstract and manuscript writing from Regeneron. Drs Forleo-Neto, Sarkar, Hou, Chan, Musser, Davis, Ramesh, Mahmood, Kim, DiCioccio, Lipsich, Braunstein, and Weinreich and Ms Kowal are Regeneron employees/stockholders. The proportion of participants receiving casirivimab and imdevimab who had 1 or more treatment-emergent adverse event was 33.5% vs 48.1% for placebo, including events related (25.8% vs 39.7%) or not related (11.0% vs 16.0%) to COVID-19.Īmong asymptomatic SARS-CoV-2 RT-qPCR-positive individuals living with an infected household contact, treatment with subcutaneous casirivimab and imdevimab antibody combination vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days.Ĭ Identifier: NCT04452318.Ĭonflict of Interest Disclosures: Drs O’Brien, Isa, Turner, Hamilton, and Herman are Regeneron employees/stockholders and have a patent pending, which has been licensed and is receiving royalties, with Regeneron. Treatment with casirivimab and imdevimab also reduced the number of high viral load weeks per 1000 participants (489.8 weeks vs 811.9 weeks with placebo P =. 03), an approximately 5.6-day reduction in symptom duration per symptomatic participant. Casirivimab and imdevimab reduced the number of symptomatic weeks per 1000 participants (895.7 weeks vs 1637.4 weeks with placebo P =. Subcutaneous casirivimab and imdevimab, 1200 mg, significantly prevented progression to symptomatic disease (29/100 vs 44/104 with placebo odds ratio, 0.54 P =. The key secondary efficacy end points were the number of weeks of symptomatic SARS-CoV-2 infection and the number of weeks of high viral load (>4 log10 copies/mL).Īmong 314 randomized participants (mean age, 41.0 years 51.6% women), 310 (99.7%) completed the efficacy assessment period 204 were asymptomatic and seronegative at baseline and included in the primary efficacy analysis. The primary end point was the proportion of seronegative participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period. ![]() Individuals were randomized 1:1 to receive 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each n = 158), or placebo (n = 156). Results from 314 individuals positive on SARS-CoV-2 reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) testing are reported. Asymptomatic individuals (aged ≥12 years) were eligible if identified within 96 hours of index case positive test collection. ![]() Randomized, double-blind, placebo-controlled, phase 3 trial of close household contacts of a SARS-CoV-2-infected index case at 112 sites in the US, Romania, and Moldova enrolled July 13, 2020-Janufollow-up ended March 11, 2021. To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. Easy-to-administer anti-SARS-CoV-2 treatments may be used to prevent progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |